Rivaroxaban
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9975 publications
Potential mechanism of Peiyuan Fumai decoction() in regulating P-selectin/ P-selectin glycoprotein ligand-1 pathway for prevention and treatment of thrombosis after total knee arthroplasty
Journal: Zhongguo gu shang = China journal of orthopaedics and traumatology
Published: June 24, 2026
Acute coronary syndrome during active infusion of andexanet alfa.
Journal: JAAPA : official journal of the American Academy of Physician Assistants
Published: June 23, 2026
Thrombosis and Survival after Prothrombin Complex Concentrate Use to treat Oral Anticoagulant Associated Haemorrhage.
Journal: The Ulster medical journal
Published: June 22, 2026
Extensive Inferior Vena Cava Thrombosis in Trauma when IVC Filter Placement Is Not Feasible Managed Using ClotTriever and FlowTriever.
Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Published: June 22, 2026
In brief: Apixaban vs rivaroxaban for acute VTE.
Journal: The Medical letter on drugs and therapeutics
Published: June 15, 2026
Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis.
Journal: Journal of the American Heart Association
Published: June 15, 2026
Rivaroxaban versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Published: June 11, 2026
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.
Journal: The New England journal of medicine
Published: June 10, 2026
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.
Journal: The New England journal of medicine
Published: June 10, 2026
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.
Journal: The New England journal of medicine
Published: June 10, 2026
Efficacy and safety of low-dose versus standard-dose direct oral anticoagulants for secondary prevention of cancer-associated thrombosis: a systematic review and meta-analysis.
Journal: Proceedings (Baylor University. Medical Center)
Published: June 10, 2026
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism. Reply.
Journal: The New England journal of medicine
Published: June 10, 2026
Last Updated: 06/30/2026